Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, provides an overview of his presentation at during the European Society for Medical Oncology (ESMO) Sarcoma & GIST Symposium 2022 on how to approach the surgical margins across soft tissue sarcoma (STS) subtypes. Dr. Rutkowski explains why a multidisciplinary team (MDT) is required for surgery, the predominant treatment strategy for STS, to obtain the STS pathological subtype, the localization of the tumor and the performance status of the patient, to subsequently enable the individualization of the procedure. For instance, to determine whether a patient will benefit from neoadjuvant or adjuvant chemotherapy and radiation therapy, such as in infiltrative subtypes of STS where neoadjuvant therapy can improve the quality of surgical margins. Additionally, Dr. Rutkowski outlines the requirements of quality surgery in GIST and retroperitoneal sarcoma (RPS). This interview took place during the European Society for Medical Oncology (ESMO) Sarcoma & GIST Symposium.
